YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Clinical trial NCT05767892 · NOT_YET_RECRUITING

Trial details

NCT number: NCT05767892
Sponsor: Suzhou Puhe Pharmaceutical Technology Co., LTD
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Start date: 2023-05-01
Primary completion: 2025-07-30
Enrollment: 350

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.